After inking a deal worth up to $75 million to acquire joint pain devicemaker Vyrsa Technologies late last year, Nevro now appears to be trying to lessen the impact of those costs on its bottom line.
Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism, led by a solid first-quarter 2024 performance and continued ...
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device ...
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback